Scientists Race To Develop Next Generation Of COVID Vaccines
The three COVID-19 vaccines available in the United States are safe and effective and were made in record time.
But they aren't ideal.
An ideal vaccine — besides being safe and effective — would have a few other desirable characteristics, says Deborah Fuller, a vaccine researcher at the University of Washington.
Such a vaccine would be "administered in a single shot, be room temperature stable, work in all demographics and, even pushed beyond that, ideally be self-administered," she says.
Now, researchers are racing to develop the next generation of COVID-19 vaccines, utilizing a variety of innovative technologies to produce more convenient and more potent options. Some of the new vaccines are already being tested in volunteers and could even be available for distribution in the next year or so.
Scientists are exploring one set of changes that should be popular with people who don't like needles.
The COVID-19 vaccine that Vaxart is developing is similar to Johnson & Johnson's in that it uses a harmless virus to deliver instructions to cells to make proteins that will prompt an immune response to the coronavirus.
But instead of putting the delivery virus in a liquid, Vaxart freeze-dries it, turning into a powder that can be formulated into a pill that can be stored at room temperature.
Another vaccine that could be self-administered is a nasal spray vaccine. Frances Lund, chair of the microbiology department at the University of Alabama at Birmingham, is working on that kind of vaccine with the biotech company Altimmune. She says that when you give people a vaccine by injection, the protection is systemic — that is, it works throughout the body.
By contrast, an intranasal vaccine induces two kinds of immunity, Lund says. You still get the systemic protection, she says, "but you will also get immunity directly at the site where you put that vaccine."
That makes it harder for the coronavirus to sneak in through the nose.
Researchers also are testing whether the tablet and nasal spray could be a single dose.
In addition to new ways to administer COVID-19 vaccines, more potent versions are also on the horizon — meaning they will get the same or better immune response from a lowered dose.
One way of doing that is to modify something called the spike protein, which prompts the immune response to the coronavirus.
Molecular biologist Jason McLellan at the University of Texas at Austin found that a synthetic form of the spike protein made a more potent vaccine if you added two amino acids called proline. Now he has made a version with six prolines.
It's a "much-improved spike" compared with the two-proline version and more stable too, McLellan says.
Another possible improvement is the way the spike protein is packaged for delivery in a vaccine.
"The size of these particles is perfect for fooling the immune system," he says.
The immune system of the person receiving the vaccine will react as if it has encountered the real virus when actually it has encountered a harmless mimic. That's the whole trick behind vaccines — getting the body's immune system ready if the real thing comes along.
Another approach to making something that looks like a virus, but really isn't, is to grow the viruslike particle in plants. It turns out that if you give plants the genetic instructions for making coronavirus proteins, they also can make synthetic particles that resemble the virus — which can then be used in a vaccine.
Dr. Brian Ward is medical officer at Medicago, one of the companies trying the plant-based approach. He says it's an unusual and positive thing to have so many different kinds of vaccines against a single disease.
"That gives us an opportunity to do some things that we've really never done before," Ward says.
He says there's some evidence that starting with one kind of vaccine and then switching to another may give better immunity than a single vaccine could do on its own.
In the end, among the most important qualities a new vaccine should have are that it should be able to be made and modified quickly in response to variants, as well as be distributed quickly.
"But a year is way too long," Lurie says. "So the aspiration right now is really to think about, 'OK, what do we need to do to do this in 100 days?' "
Lurie says it's virtually certain the world will face new and dangerous microbes that will necessitate vaccines that are "safe and effective, fast, easy to use, preferably a single dose."
That way, she says, "when the next one comes, we're much closer to the starting gate than we even were for this one." Copyright 2021 NPR. To see more, visit https://www.npr.org.
ARI SHAPIRO, HOST:
There are now three COVID-19 vaccines available in the United States. And while they are all effective, scientists are already working on the next generation of vaccines to fight the coronavirus, which they hope will be even better. NPR's Joe Palca has this survey of what's on the horizon.
JOE PALCA, BYLINE: The vaccines currently available in this country are safe and effective, but vaccine developer Deborah Fuller at the University of Washington says the ideal vaccine has some other properties
DEBORAH FULLER: Administered in a single shot - right? - be room temperature stable and work in all demographics. And even push beyond that - ideally be self-administered.
PALCA: And vaccines with those characteristics are now making their way through the development pipeline. Take self-administered. Sean Tucker is chief scientific officer at Vaxart.
SEAN TUCKER: We want to develop a platform technology where we could easily give a vaccine and obviously the easiest format to give would be a tablet.
PALCA: The Vaxart COVID tablet vaccine has begun testing in humans. Another vaccine that could be self-administered is a nasal spray. Frances Lund at the University of Alabama, Birmingham is working on one with the biotech company Altimmune. She says when you give people a vaccine by injection, the protection is systemic. That is, it works throughout the body.
FRANCES LUND: By contrast, if you give the vaccine intranasal, you induce two kinds of immunity.
PALCA: You still get the systemic protection.
LUND: But you will also get immunity directly at the site where you put that vaccine.
PALCA: Making it harder for the coronavirus to sneak in through your nose. In addition to new ways to administer COVID vaccines, there are also changes on the horizon for something called the spike protein, the protein that prompts the immune response to the coronavirus. Molecular biologist Jason McLellan at the University of Texas at Austin found that a synthetic form of the spike made a more potent vaccine if you swapped in two amino acids called proline. Now he's made a version with six prolines swapped in.
JASON MCLELLAN: That is a much-improved spike compared to the two-proline version. The protein is much more stable.
PALCA: Another improvement on the horizon is the way the spike protein is packaged for delivery in a vaccine. Jeff Baxter is CEO of VBI Vaccines. He says his company is making a vaccine that's a better mimic of the real coronavirus.
JEFF BAXTER: The size of these particles is perfect for fooling the immune system.
PALCA: Fooling it into thinking it's seeing the real virus when it's just seen a harmless mimic. That's the whole trick behind vaccines. Get the body's immune system ready if the real thing ever comes along. Another kind of approach to making something that looks like a virus but really isn't is to grow the virus-like particles in plants. Turns out you can give plants the genetic instructions for making proteins in the coronavirus, and they'll churn out the vaccine. Brian Ward is medical officer at Medicago, one of the companies trying this approach. He says it's an unusual and positive thing to have so many different kinds of vaccines against a single disease.
BRIAN WARD: That gives us an opportunity to do some things that we've really never done before.
PALCA: Starting with one kind of vaccine and then switching to another may give better immunity than a single vaccine could do on its own. In the end, probably the most important quality a new vaccine must have is the ability to make it and modify it quickly in response to new variants and distribute it rapidly. Nicole Lurie is strategic advisor at CEPI, the Coalition for Epidemic Preparedness Innovations. Some of these new vaccines under development could be available within the year, but Lurie says that's not good enough.
NICOLE LURIE: The year is way too long. And so the aspiration right now is really to think about, OK, what do we need to do to do this in 100 days?
PALCA: Lurie says it's virtually certain the world will face other new and dangerous microbes that will need a vaccine that is...
LURIE: Safe and effective, fast, easy to use, preferably single dose so that when the next one comes, we're much closer to the starting gate than we even were for this one.
PALCA: And she cautions that to do that, scientific advances are needed, but so are regulatory and social changes and maybe a bit more humility and understanding that a microbe can indeed bring the world to its knees.
Joe Palca, NPR News. Transcript provided by NPR, Copyright NPR.